X0708 D LIVE 0001857044 Indaptus Therapeutics, Inc. 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 347-480-9760 DELAWARE INTEC PARENT, INC. Intec Parent Inc. Corporation true 2021 JEFFREY A. MECKLER 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Executive Officer Director WALT A LINSCOTT 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Executive Officer NIR SASSI 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Executive Officer MICHAEL NEWMAN 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Executive Officer Director HOONMO LEE 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Director HILA W. KARAH 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Director ANTHONY J. MADDALUNA 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Director WILLIAM B. HAYES 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Director ROGER J. POMERANTZ 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Director BRIAN O'CALLAGHAN 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY NEW YORK 10019 Director Pharmaceuticals Decline to Disclose 06b false 2021-07-23 false true true true The Private Placement is consummated to satisfy a closing condition of the merger agreement between the Company, Intec Israel, Domestication Merger Sub Ltd,, Dillon Merger Subsidiary, Inc. and Decoy Biosystems, Inc., which was announced on March 15, 2021. 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 30000000 30000000 0 Offering and issuance of an unregistered pre-funded warrant to purchase up to 2,727,273 shares of Common Stock and an accompanying unregistered warrant to purchase up to 2,727,273 shares of Common Stock. false 1 2100000 0 $420,000 of the $2,100,000 is paid to Ladenburg Thalmann and Maxim Group, as financial advisors. Wainwright also entitled to: management fee of 1.75% of the proceeds, $25,000non-accountable expense, $50,000legal fees, 136,364 warrants at $13.75 per share. 0 Issuer expects to use proceeds from the offering for working capital purposes, which includes payment of salaries to the named executive officers. false Indaptus Therapeutics, Inc. /s/ Nir Sassi Nir Sassi Chief Financial Officer 2021-08-05